BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.37.0//EN
X-ORIGINAL-URL:https://www.igf.cnrs.fr/
X-WR-CALNAME:IGF
X-WR-CALDESC:Institut de génomique fonctionnelle
X-WR-TIMEZONE:Europe/Paris
BEGIN:VTIMEZONE
TZID:Europe/Paris
X-LIC-LOCATION:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=4SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-5f7695debd8cde8db5abcb9f161b49ea@igf.cnrs.fr
DTSTART;TZID=Europe/Paris:20261127T140000
DTEND;TZID=Europe/Paris:20261127T170000
DTSTAMP:20261028T162102Z
CREATED:20261028
LAST-MODIFIED:20261028
PRIORITY:5
SEQUENCE:5
TRANSP:OPAQUE
SUMMARY:Thesis – Gawain GRELLIER
DESCRIPTION:Genetically controlled apoptosis of dopaminergic neurons: correction of sensorimotor deficits using a T-type calcium channel inhibitor\n \nJury\n\nPascal FOSSAT, Professor, Institute for Neurodegenerative Diseases, Bordeaux – Reviewer\nMichel BARROT, Research Director, Institute of Cellular and Integrative Neuroscience, Strasbourg – Reviewer\nGaëtan POULEN, Professor-Hospital Physician, University of Montpellier – Examiner\nVéronique COIZET, Research Scientist, Grenoble Institut des Neurosciences – Examiner\nAmaury FRANÇOIS, Research Scientist, IGF, University of Montpellier – Co-supervisor\nEmmanuel BOURINET, Research Director, IGF, University of Montpellier – Thesis supervisor\n\n \nSummary\nParkinson’s disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). Beyond motor symptoms, it involves sensory abnormalities and chronic pain, which often appear early and resist dopaminergic treatments. However, current preclinical models mostly mimic advanced stages induced instantaneously, which limits the study of early disease phases. We exploited the caspase-3 pathway, the main mediator of apoptosis in these neurons, by expressing an inducible caspase-3 (taCasp3) specifically in SNc dopaminergic neurons using the CreERT2 system (TH-CreERT2 mice). Increasing tamoxifen doses allow progressive, specific ablation, in order to establish a causal link with the sequence of sensory and then motor deficits. Strong induction caused marked SNc degeneration in both male and female mice, with motor deficits and mechanical hypersensitivity. Progressive ablation showed that tactile allodynia appears well before motor symptoms. Finally, a blood-brain barrier-penetrant T-type calcium channel inhibitor acutely reversed this tactile hypersensitivity. This model faithfully reproduces the clinical timeline of sensory and motor signs in PD and is a promising tool to investigate the mechanisms of parkinsonian pain and to evaluate therapies targeting non-motor symptoms.\n
URL:https://www.igf.cnrs.fr/en/events/thesis-gawain-grellier/
CATEGORIES:Thesis
LOCATION:amphitéâtre Saint Priest
ATTACH;FMTTYPE=image/jpeg:https://www.igf.cnrs.fr/wp-content/uploads/2026/10/photo-Gawain-Grellier.jpg
END:VEVENT
END:VCALENDAR